Royal Bank of Canada’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-7
Closed 6928
2024
Q2
$0 Buy
7
+5
+250% +$182 ﹤0.01% 7110
2024
Q1
$0 Sell
2
-25
-93% -$906 ﹤0.01% 7076
2023
Q4
$1K Buy
27
+20
+286% +$705 ﹤0.01% 6903
2023
Q3
$0 Sell
7
-7
-50% -$264 ﹤0.01% 7141
2023
Q2
$0 Buy
+14
New +$536 ﹤0.01% 7307
2023
Q1
Sell
-2,792
Closed -$211K 7122
2022
Q4
$211K Sell
2,792
-121
-4% -$11.3K ﹤0.01% 4832
2022
Q3
$280K Sell
2,913
-167
-5% -$23.4K ﹤0.01% 4486
2022
Q2
$518K Buy
3,080
+417
+16% +$63.4K ﹤0.01% 4069
2022
Q1
$493K Buy
2,663
+122
+5% +$25.3K ﹤0.01% 4286
2021
Q4
$680K Sell
2,541
-1,189
-32% -$312K ﹤0.01% 4212
2021
Q3
$1.09M Buy
3,730
+1,391
+59% +$406K ﹤0.01% 3598
2021
Q2
$579K Buy
2,339
+1,702
+267% +$438K ﹤0.01% 4143
2021
Q1
$182K Sell
637
-22
-3% -$8.78K ﹤0.01% 5023
2020
Q4
$184K Buy
659
+313
+90% +$116K ﹤0.01% 4920
2020
Q3
$141K Buy
346
+99
+40% +$50.9K ﹤0.01% 4767
2020
Q2
$143K Buy
247
+194
+366% +$88.6K ﹤0.01% 4642
2020
Q1
$12K Buy
+53
New +$9.19K ﹤0.01% 5755

Other funds holding CODX

Royal Bank of Canada's CODX Position: Q3 2024 in Review

Royal Bank of Canada sold out of Co-Diagnostics (CODX) in Q3 2024, closing a stake of 7 shares.

Royal Bank of Canada first reported a position in CODX in Q1 2020 and held it in 17 quarters. The position peaked at $1.09M in Q3 2021. 36 funds tracked by Wall St. Rank hold CODX as of Q3 2024.

  • Royal Bank of Canada reported no remaining Co-Diagnostics position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 7 Co-Diagnostics shares in Q3 2024.
  • Royal Bank of Canada first reported a position in Co-Diagnostics in Q1 2020 and held it in 17 quarters.
  • Royal Bank of Canada's Co-Diagnostics position peaked at $1.09M in Q3 2021.
  • 36 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.